Data show minimal risk of stopping DMTs in older MS patients with stable disease. Now, the focus has shifted to understanding the potential risks of staying on treatment.

Patients with relapse-onset MS who have been stable for at least 5 years on DMT have a higher risk of recurrence if they stop therapy. Discontinuation of first-line disease-modifying therapy (DMT) ...

MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

They are indicated for adults with relapsing forms of MS. In the end, starting and sticking to a DMT—even if you have to ...

A simple treatment algorithm to aid in the selection of appropriate DMTs reduces racial disparities in patients with ...

The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...

There’s no cure for MS, but treatment can help manage the symptoms and slow the progression of the disease. These treatment options are known as disease-modifying therapies (DMTs). A main DMT ...

He cited data that show about 40% of patients with MS aged older than 60 years in the United States still use DMT. Peak use occurs between age 41 to 50 years. Corboy reviewed data from the DISCOMS ...

Be sure to carefully discuss with your MS healthcare provider whether the potential benefits of the DMT you are considering ...

Biogen’s commitment to MS management extends beyond understanding the pathogenic role of CNS-targeted autoimmunity and traditional DMT research to fostering innovative treatment initiatives ...